In all five cases, ON101 demonstrated consistent epithelialization and wound improvement in both acute and residual burns. All wounds showed reductions in inflammation, exudate, and pain. ON101 was well tolerated in children, immunosuppressed patient, and patient with diabetic and vascular comorbidities. Scar assessment after ON101 treatment suggested uniform and soft remodeling.
ON101 supported efficient healing, reduced inflammation, relieved pain, and promoted favorable scar outcomes in both acute and residual burn wounds. It may serve as a novel and effective first-line option for managing acute, complex or chronic burns, supporting both wound repair and patient comfort.
Burn injuries, whether acute or residual, often involve prolonged inflammation, persistent pain, delayed epithelialization, and risk of hypertrophic scarring. This case series evaluated ON101 topical cream as a reparative therapy in inpatient burn care, focusing on its effects on healing speed, symptom relief, and safety across diverse clinical cases.